Perspectives on Safety and Efficacy-The BOLD Phase 2 Extension Study of Siponimod in Relapsing-Remitting Multiple Sclerosis. Hammond ER JAMA Neurol. 2016 Jul 5. PMID: 27380179. Abstract CommentRecommendBookmarkWatch
